Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Spliceostatin treatment on HeLa cells

ABSTRACT: HeLa cell line treated with Spliceostatin or methanol

ORGANISM(S): Homo sapiens

PROVIDER: GSE22614 | GEO | 2011/03/08

SECONDARY ACCESSION(S): PRJNA128345

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Spliceostatin treatment on HeLa cells

Project description:HeLa cell line treated with Spliceostatin or methanol Three biological replicates and one technical replicate were labeled in direct and dye-swap experiments.

2011-03-08 | E-GEOD-22614 | biostudies-arrayexpress

Human telomerase RNA processing and quality control

2015-11-25 | GSE72055 | GEO

Deep RNA sequencing of HeLa secreted exosomes after 10ng/ml TGF-b1 treatment or no treatment

Project description:Deep RNA sequceing was performed to explore the expression level of miRNAs in HeLa cell exosomes after treatment with or without 10 ng/ml TGF-β1 for 24 h. The results showed that 48 miRNAs were enriched in exosomes of HeLa cells after treated with TGF-β1 compared with non-treated cells (negative control), proving that TGF-β1 affects HeLa cell exosomes miRNA profile.

2021-02-17 | GSE163507 | GEO

Human telomerase RNA processing and quality control

Project description:RNA sequencing of HeLa cells treated with siRNA against the RNA exosome components hRRP40, hRRP6, hDIS3, and hRRP6/hDIS3 or the splicing inhibitors Isoginkgetin and spliceostatin A, respectively. Stranded, ribo-depleted RNA seq profiles of HeLa cells treated with exosome targeting siRNAs or splicing inhibitors using Illumina HiSeq. All experiments were carried out in triplicate starting with independent cell cultures

2015-11-25 | E-GEOD-72055 | biostudies-arrayexpress

Effect of splicing on histone H3 K36 methylation

Project description:Histone H3 K36me3 and RNA pol II were localized by ChIP before and after inhibition of splicing by spliceostatin for 12 hr. Total matched reads for the control and SSA treated Hela samples were 11.6 and 8.2 million for anti-H3K36me3 and 6.6 and 5.0 million for anti-pol II.

2011-09-05 | GSE30895 | GEO

HeLa cells treated with V-ATPase inhibitors or with desoxyferramine compared to HeLa in DMSO or medium with low LDL

Project description:Expression data from HeLa cells treated with V-ATPase inhibitors or with desoxyferramine compared to HeLa treated with DMSO or medium with low LDL To determine which genes respond first to low concentrations of V-ATPase inhibition, we treated HeLa cells with two different V-ATPase inhibitors, bafilomycin and phenylsalicylihalamide (LX1077) at concentrations that slow cell growth by only 20%. To identify genes responding to expected effects of inhibiting the V-ATPase, expression data from inhibiting the V-ATPase was compared to that of chelating iron or incubating cells in medium with low LDL.

2010-07-22 | GSE16870 | GEO

RNA-Seq of HeLa cells

Project description:HeLa cells were treated with ActD and RNA sequenced to examine RNA stability

2022-03-10 | GSE198178 | GEO

Effect of depletion of ESRRB on gene expression in HeLa cells

Project description:To investigate the role of ESRRB in cervical carcinogenesis, we established an ESRRB knockout HeLa cell line.

2023-04-14 | GSE229349 | GEO

Homo sapiens

Project description:Spliceostatin treatment on HeLa cells

| PRJNA128345 | ENA

HeLa Cell Genome Sequencing Studies

Project description:<p>This study contains all authorized whole genome sequence data of the HeLa cell line from datasets currently in dbGaP. These data have been approved for health, medical, and/or biomedical research purposes. Access to these data can be granted for one year. Accessible data will include the studies listed on this page and any additional authorized datasets that become available during this one-year period.</p> <p><a href="http://acd.od.nih.gov/hlgda.htm">The HeLa Genome Data Access Working Group of the Advisory Committee to the Director (ACD)</a> will review requests from the research community for access to these datasets and assess whether the requests align with the terms of use defined in the HeLa Genome Data Use Agreement. The Working Group's findings will be reported to the ACD, and the ACD will make recommendations to the NIH Director about whether a request should be approved or disapproved. The NIH Director will decide whether access to the data will be granted.</p>

| phs000640 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data